These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6386891)

  • 1. Distribution and concentration of cyclosporin in human blood.
    Atkinson K; Britton K; Biggs J
    J Clin Pathol; 1984 Oct; 37(10):1167-71. PubMed ID: 6386891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin-A radioimmunoassay: a modified method for whole blood determination.
    Randall G; Jacobs P
    Exp Hematol; 1985 Oct; 13(9):874-8. PubMed ID: 4043265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of cyclosporin A in human serum.
    Smith JM; Hows JM; Gordon-Smith EC
    J Clin Pathol; 1983 Jan; 36(1):41-3. PubMed ID: 6822676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of cyclosporin G (NVa2 cyclosporin) in blood and plasma.
    Yatscoff RW; Honcharik N; Lukowski M; Thliveris J; Chackowsky P; Faraci C
    Clin Chem; 1993 Feb; 39(2):213-7. PubMed ID: 8432008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of temperature and endogenous factors in blood on concentrations of cyclosporin in plasma measured by high-performance liquid chromatography.
    Shibata N; Minouchi T; Hayashi Y; Shibata H; Ono T; Shimakawa H
    Chem Pharm Bull (Tokyo); 1989 Jul; 37(7):1877-80. PubMed ID: 2805168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sample preparation on concentrations of cyclosporin A measured in plasma.
    Yatscoff RW; Rush DN; Jeffery JR
    Clin Chem; 1984 Nov; 30(11):1812-4. PubMed ID: 6488526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration.
    Lensmeyer GL; Wiebe DA; Carlson IH
    Clin Chem; 1989 Jan; 35(1):56-63. PubMed ID: 2642763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.
    Lemaire M; Tillement JP
    J Pharm Pharmacol; 1982 Nov; 34(11):715-8. PubMed ID: 6129301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.
    Legg B; Gupta SK; Rowland M; Johnson RW; Solomon LR
    Eur J Clin Pharmacol; 1988; 34(5):451-60. PubMed ID: 3203704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin: erythrocyte binding and an examination of its use to estimate unbound concentration.
    Legg B; Rowland M
    Ther Drug Monit; 1988; 10(1):16-9. PubMed ID: 3376178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of cyclosporin.
    Ptachcinski RJ; Venkataramanan R; Burckart GJ
    Clin Pharmacokinet; 1986; 11(2):107-32. PubMed ID: 3514043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring cyclosporin concentrations in marrow transplant recipients: comparison of two assay methods.
    Yee GC; Kennedy MS; Gmur DJ; Self SG; Deeg HJ
    Bone Marrow Transplant; 1987 Feb; 1(3):289-95. PubMed ID: 3332139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of cyclosporin A on peripheral blood and bone marrow T lymphocyte colony formation.
    Foa R; Catovsky D
    Clin Exp Immunol; 1981 Aug; 45(2):371-5. PubMed ID: 6976245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin neurotoxicity in patients treated with allogeneic bone marrow transplantation.
    Labar B; Bogdanic V; Plavsic F; Francetic I; Dobric I; Kastelan A; Grgicevic D; Vrtar M; Grgic-Markulin L; Balabanic-Kamauf B
    Biomed Pharmacother; 1986; 40(4):148-50. PubMed ID: 3539218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.
    Legg B; Rowland M
    Pharm Res; 1988 Feb; 5(2):80-5. PubMed ID: 3073383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of post-transplant methotrexate, cyclosporin A and prednisolone on graft rejection after allogeneic bone marrow transplantation.
    Uharek L; Gassmann W; Fleischhauer D; Wottge HU; Loeffler H; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1991 Jan; 7(1):17-22. PubMed ID: 2043873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted blood levels of cyclosporin for cardiac transplantation.
    Griffith BP; Hardesty RL; Trento A; Lee A; Bahnson HT
    J Thorac Cardiovasc Surg; 1984 Dec; 88(6):952-7. PubMed ID: 6389991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A serum and blood levels in marrow graft recipients: correlation with administered dose, serum creatinine and graft-versus-host disease.
    Bacigalupo A; Di Giorgio F; Frassoni F; Van Lint MT; Raffo MR; Gogioso L; Viale M; Marmont AM
    Acta Haematol; 1984; 72(3):155-62. PubMed ID: 6438979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model to account for the blood-to-plasma distribution of cyclosporin A in human blood.
    Shibata N; Minouchi T; Ono T; Shimakawa H
    J Pharmacobiodyn; 1990 Jan; 13(1):20-9. PubMed ID: 2341967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds.
    Herrlinger JD; Alsen C; Beress R; Hecker U; Weikert W
    J Rheumatol Suppl; 1982; 8():81-9. PubMed ID: 6813496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.